Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 35 results for "sarabjit kour nangra"

We have buy call on Sun Pharma, Ranbaxy: Sarabjit Kour Nangra,...

Lupin is correcting to realistic levels ET Now: If you can tell us what 483 means for Mandideep plant and what essentially can it mean for Lupin as a brand? Sarabjit Kour Nangra: In terms of approvals and other things, things might get impacted by the 483 and ... Economic Times, 1 month ago
Rediff.com

IT results: Top 4 perform differently in March quarter

The results of the March quarter have shown further polarity in the performance of the top four information technology (IT) services companies. The top two, Tata Consultancy Services (TCS) and Infosys, have reported better than expected numbers.
 Smart Investor3 days ago

HCL Tech net increases 14.4 % in third quarter

HCL Technologies, the country's fourth largest IT services provider, registered a 14.4 per cent increase in net profit to Rs.1,926 crore in the last quarter of 2015-16. The company had reported a net profit of Rs.1,683 crore in the same quarter a ...
 The Hindu3 days ago HCL Tech falls 5% post Q3; brokerage maintains 'buy'  Business Today India3 days ago HCL Tech Underperforms Its Three Bigger IT Rivals, Shares Slump  NDTV3 days ago

Wipro Q4 in line; Q1FY17 guidance disappointing: Analysts

With Wipro posting a mixed set of Q4 results on Wednesday, analysts say that the numbers are broadly in-line with expectations. Giving its guidance for Q1FY17, Wipro expects a 1-3 percent growth which disappointed the street estimates of around 3-5 ...
 Moneycontrol.com1 week ago Infosys beats expectations in Q4; here's how D-Street analysts dissect results  Economic Times2 weeks ago Infosys beat expectations in Q4; here's how D-Street analysts reacted  Economic Times2 weeks ago

TCS beats estimates, Q4 net at Rs 6,341 cr

Tata Consultancy Services Ltd, India's biggest software services exporter, beat analyst expectations to post a 64 per cent rise in the fourth quarter net profit, helped by good demand in key markets in North America and Continental Europe. The firm ...
 The Hindu1 week ago

TCS FY16 revenue crosses Rs 1 lakh-crore mark

Tata Consultancy Services (TCS) on Wednesday became the first Indian IT company to have crossed the trillion-rupee mark in revenue as it recorded a 14.8 per cent rise in topline at Rs 1.08 lakh crore for FY16. Its bottom line grew 22.4 per cent to 24,292 ...
 The Financial Chronicle1 week ago TCS beats street with 73% jump in net,sounds upbeat about FY17  Press Trust of India1 week ago TCS Q4 margins disappoint but FY17 outlook good: Analysts  Moneycontrol.com1 week ago
Business Standard India

HealthCare Global shares plunge 21% on debut

Its IPO was oversubscribed 55 per cent. Oncology chain HealthCare Global Enterprises Ltd (HCG) failed to enthuse investors on its stock-market debut on Wednesday as its shares slumped. HCG's disappointing debut comes on the back of spectacular ...
 VC Circle1 month ago Health-care stocks unlikely to rerate more  Smart Investor1 month ago Healthcare scrips unlikely to rerate further  Smart Investor1 month ago

Aurobindo stock outshines peers

With current market capitalisation of Rs 43,480 crore, Aurobindo Pharma is the fourth largest pharma company, after Sun Pharmaceuticals Industries (Rs 2,01,300 crore), Lupin (Rs 69,200 crore), and Dr. Reddy’s Laboratories (Rs 54,300 crore). However, the ...
 The Financial Chronicle1 month ago
Livemint.com

Drug ban: Wockhardt and Laborate get interim stay from Delhi high court

citing health risks; the move was based on a report by a six-member committee headed by Chandrakant Kokate New Delhi: Two more drug makers—Wockhardt Ltd and Laborate Pharmaceuticals—have won stay order from the Delhi high court against the ...
 Livemint.com1 month ago
Business Standard India

USFDA rap to Lupin unit pulls down stock

The US Food and Drug Administration (FDA)'s observations on Lupin's Goa plant made the Street nervous with the stock falling nearly seven per cent on Tuesday. The company, in a clarification to the stock exchanges, said the US FDA had inspected its ...
 Smart Investor1 month ago USFDA concerns see Lupin tank 7%  Smart Investor1 month ago USFDA concerns give jitters to the street  Smart Investor1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sarabjit kour nangra
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less